香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公告所提述的本公司證券的邀請或要約。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6998） 公告 (1)非常重大收購事項及關連交易－合併附屬公司與標的公司之間涉及 根據特定授權發行代價股份的建議合併； (2)涉及新上市申請的反向收購； (3)申請清洗豁免； (4)有關股東人員留任計劃的特別交易； (5)建議更改公司名稱； (6)建議增加本公司法定股本；及 (7)建議採納一次性購股權計劃 每月最新情況及延遲寄發通函 如本公司日期為2025年4月15日的公告所披露，本公司已於2025年4月15日透過 其聯席保薦人向聯交所提交新上市申請。此外，如本公司日期為2025年10月27日 的公告所披露，寄發通函的時間已延長至2025年11月30日或之前。本公司謹此知 會股東 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 嘉和生物藥業（開曼）控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06998 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.00002 | USD | | 20,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.00002 | USD | ...

(1)非常重大收購事項及關連交易－合併附屬公司與標的公司之間涉及 根據特定授權發行代價股份的建議合併； (2)涉及新上市申請的反向收購； 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公告所提述的本公司證券的邀請或要約。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6998） 公告 (3)申請清洗豁免； (4)有關股東人員留任計劃的特別交易； (5)建議更改公司名稱； 警告 (6)建議增加本公司法定股本；及 (7)建議採納一次性購股權計劃 每月最新情況及延遲寄發通函 茲提述嘉和生物藥業（開曼）控股有限公司（「本公司」）(i)日期為2024年10月7日的 公告（「第一份公告」），內容有關（其中包括）建議合併、新上市申請、清洗豁免、 股東人員留任計劃、建議更改公司名稱、建議增加本公司法定股本及建議採納一 次性購 ...

Market Overview - The market has shown volatility, with significant declines in major indices and stocks over the past two weeks, including a drop of over 13% in the Ample Hang Seng Technology Index and over 14% in the Hang Seng Biotechnology Index [1] - Notable declines in individual stocks include Tencent, which fell nearly 80 yuan, and SMIC, which dropped over 26% [1] - Despite a rise in gold prices by over $150, gold stocks like Zijin Mining and Shandong Gold experienced weekly declines [1] Financial Data Insights - As of the end of September, M2 growth was at 8.4% and M1 growth at 7.2%, indicating enhanced liquidity and economic activity [2] - PMI has been below 50 for six consecutive months, suggesting weak production expansion intentions among enterprises [2] - A significant increase in household deposits by 760 billion yuan in September indicates a shift towards saving rather than investing in the stock market [2] Corporate Developments - In the U.S. market, AI-related developments dominated headlines, with OpenAI partnering with Broadcom for AI chips and Apple launching the M5 chip [5] - Oracle Cloud plans to deploy 50,000 AMD chips, and Nvidia announced a $40 billion acquisition of Aligned, marking significant corporate activity in the AI sector [5] - Major investment banks reported substantial increases in fee income, with Goldman Sachs seeing a 42% rise, driven by a surge in merger and acquisition activity [5] IPO and New Listings - Recent IPOs in Hong Kong showed strong initial performance, with companies like Zhida Technology and Xuanzhu Biotechnology seeing significant gains in their dark pool trading [6] - However, some listings faced challenges, such as delays and underperformance, indicating a mixed sentiment in the IPO market [6] Historical Context and Investment Strategy - Historical analysis of the Persian Wars highlights the importance of strategic decision-making in both warfare and investment, emphasizing the need for calculated risks and emotional balance [9][10] - The current market environment suggests that maintaining a balanced investment approach, with a reserve of cash for opportunities, is prudent [11][12]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 嘉和生物藥業（開曼）控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06998 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.00002 USD | | 20,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.00002 USD | | 20,000 | 本月底法定/註 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公告所提述的本公司證券的邀請或要約。 GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6998） 公告 (1)非常重大收購事項及關連交易－合併附屬公司與標的公司之間涉及 根據特定授權發行代價股份的建議合併； (2)涉及新上市申請的反向收購； (3)申請清洗豁免； (4)有關股東人員留任計劃的特別交易； (5)建議更改公司名稱； (6)建議增加本公司法定股本；及 (7)建議採納一次性購股權計劃 每月最新情況 茲提述嘉和生物藥業（開曼）控股有限公司（「本公司」）(i)日期為2024年10月7日的 公告（「第一份公告」），內容有關（其中包括）建議合併、新上市申請、清洗豁免、 股東人員留任計劃、建議更改公司名稱、建議增加本公司法定股本及建議採納一 次性購股權計劃（統稱「交易 ...

Operational Efficiency and Strategy - The company achieved significant operational efficiency by implementing a "focus, optimize, accelerate, and expand" strategy, resulting in a substantial reduction in operating costs during the reporting period[7]. - The company has successfully reduced operational costs while expanding its strategic partnerships and advancing new drug approvals[7]. - The company successfully achieved a light-asset operation model, effectively reducing operational costs while actively promoting strategic collaborations, including a proposed merger with Yiteng Pharmaceutical[24]. Drug Development and Approvals - The innovative drug, Laroisilib (GB491), received approval from the National Medical Products Administration (NMPA) on May 27, 2025, for treating HR+/HER2- locally advanced or metastatic breast cancer[7]. - The company reported that the Phase III clinical trial for Laroisilib in combination with Letrozole met its primary endpoint, leading to NMPA approval for its new drug application on May 27, 2025[11]. - GB268, an innovative trispecific antibody targeting PD-1, VEGF, and CTLA-4, completed GLP toxicology studies and received IND approval from NMPA on July 17, 2025[12]. - The NDA for GB491 was accepted by NMPA on March 28, 2023, for use in specific breast cancer treatments, and it was approved for marketing on May 27, 2025[27]. - GB268 completed two batches of GMP pilot production in the first half of 2025, showing good batch-to-batch consistency, high purity, and stability, with clinical research use approved[28]. - GB263T's I/II clinical trial has completed the dose escalation phase, showing promising efficacy at treatment doses of 1,260-1,680 mg in non-small cell lung cancer patients[28]. Financial Performance - Total revenue for the reporting period was approximately RMB 32.2 million, primarily due to a licensing and equity agreement with TRC 2004, Inc., while for the six months ending June 30, 2024, it was approximately RMB 14.5 million[23]. - Total comprehensive loss for the reporting period was approximately RMB 54.3 million, while for the six months ending June 30, 2024, it was approximately RMB 141.0 million, primarily due to reduced expenses[23]. - The company reported a net loss of approximately RMB 54.4 million for the reporting period, a decrease from a net loss of about RMB 135.1 million for the six months ended June 30, 2024[72]. - Revenue for the six months ended June 30, 2025, was RMB 32,245,000, compared to RMB 14,470,000 for the same period in 2024, representing a growth of 123.5%[189]. - The net loss for the period was RMB 54,373,000, compared to RMB 135,055,000 in the previous year, a reduction of 59.8%[189]. Strategic Collaborations and Mergers - The company entered into a merger agreement with Eton Pharmaceuticals on September 13, 2024, aiming to enhance R&D capabilities and market expansion through synergistic effects[8]. - The company has submitted a new listing application related to the proposed merger with Eton Pharmaceuticals to the Hong Kong Stock Exchange on April 15, 2025[8]. - The company aims to enhance its market competitiveness through deep integration across R&D, sales, production, and finance following the proposed merger[8]. - On September 13, 2024, the company entered into a merger agreement with Yiteng Pharmaceutical, with the original shareholders of Yiteng expected to hold approximately 77% of the enlarged issued shares post-merger[25]. - The company and Yiteng Pharmaceutical are processing regulatory feedback regarding the merger and new listing application, with updates expected[25]. Research and Development - The company is focused on core pipeline development and new drug approvals, with significant progress in clinical trials and regulatory submissions[11]. - The company is actively pursuing strategic collaborations and pipeline advancements, including the development of two trispecific antibodies in partnership with Eton Pharmaceuticals[9]. - The company has completed multiple preclinical candidate compound developments, focusing on first-in-class (FIC) and best-in-class (BIC) potential targets[16]. - The company is in the discovery phase for several undisclosed candidate molecules, indicating ongoing innovation efforts[18]. - The company is advancing the localization of GB491 production technology and has begun preparations for its commercialization[41][42]. Clinical Trial Results - GB261 (CD20/CD3) has shown promising efficacy and good safety in I/II clinical trials for lymphoma, with initial results presented at the 65th ASH Annual Meeting[13]. - GB261's I/II clinical trial results were presented at the 65th American Society of Hematology (ASH) annual meeting, showcasing its superior safety and efficacy balance in B-NHL patients who failed multiple prior therapies[49]. - The LEONARDA-1 clinical trial showed that GB491 combined with Fulvestrant significantly reduced the risk of disease progression and death by over 50% in patients previously treated with endocrine therapy[39]. - GB263T demonstrated an objective response rate (ORR) of 28.6% in patients with EGFR-sensitive mutations who progressed after third-generation TKI treatment, with some patients showing benefits for over 12 months[54]. Cost Management and Efficiency - Research and development expenses for the reporting period were approximately RMB 74.6 million, while for the six months ending June 30, 2024, it was approximately RMB 109.7 million, with the decrease mainly attributed to reduced employee benefits and lower new drug development and clinical trial expenses[23]. - Administrative expenses decreased by 34.8% from approximately RMB 38.5 million to about RMB 25.1 million, primarily due to reduced employee benefits expenses[69]. - Continuous optimization of CMC quality and efficiency has led to reduced production costs and improved supply chain stability[31]. - The CMC team is optimizing production processes and reducing costs through domestic sourcing of materials, enhancing supply chain stability and improving cash flow efficiency[53]. Stock Options and Incentives - The total number of unexercised stock options as of June 30, 2025, is 3,162,832 shares, with 59,000 shares exercised during the reporting period[109]. - The maximum number of shares that can be received by Mr. Wong under various share option plans is 1,250,000 shares[96]. - The maximum number of shares that can be received by Dr. Guo under various share option plans is 9,756,861 shares[96]. - The exercise price for stock options granted ranges from $0.0002 to $2 per share, with various vesting periods based on performance milestones[107]. - The plan aims to incentivize selected participants through the post-IPO stock option plan to contribute to its growth and development[111]. Future Outlook and Plans - The company is focusing on potential global oncology and autoimmune disease FIC and BIC innovative pipelines, aiming to address unmet medical needs in China and globally[64]. - The application and negotiation for the inclusion of GB491 in the national medical insurance catalog are expected to be completed by the end of 2025, with commercialization anticipated before the end of 2025[64]. - The company plans to submit a new listing application for the proposed merger to the Stock Exchange, expected to be completed in the second half of 2025[64].

Group 1 - The company announced the issuance of 684,100 shares due to the vesting of restricted share units under the 2023 Restricted Share Unit Plan adopted on October 27, 2023 [1] - The company issued 906,600 shares as a result of the exercise of stock options by the CEO under the 2023 Stock Option Plan [1] - Additionally, 284,400 shares were issued due to the exercise of stock options by eligible employees under the post-IPO Stock Option Plan [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 嘉和生物藥業（開曼）控股有限公司 確認 呈交日期： 2025年9月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 06998 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | ...

公司名稱: 嘉和生物藥業（開曼）控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06998 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | 0.00002 | USD | | 20,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | 0.00002 | USD | | 20,000 | 本月底法定/註冊股本總額： USD 20,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 ...